Perälä M - Search Results

1

Safety of tacrolimus 0.03% and 0.1% ointments in young children with atopic dermatitis: a 36-month follow-up study.

Salava A, Perälä M, Pelkonen A, Mäkelä M, Remitz A. Salava A, et al. Among authors: perala m. Clin Exp Dermatol. 2022 May;47(5):889-902. doi: 10.1111/ced.15024. Epub 2022 Jan 13. Clin Exp Dermatol. 2022. PMID: 34798685

2

Young children with moderate-to-severe atopic dermatitis can be treated safely and effectively with either topical tacrolimus or mild corticosteroids.

Perälä M, Ahola M, Mikkola T, Pelkonen AS, Remitz A, Mäkelä MJ. Perälä M, et al. Acta Paediatr. 2020 Mar;109(3):550-556. doi: 10.1111/apa.15001. Epub 2019 Oct 7. Acta Paediatr. 2020. PMID: 31483891 Clinical Trial.

3

Are Infants and Toddlers with Moderate-to-severe Atopic Dermatitis Undertreated? Experiences of a Finnish Tertiary Care Hospital.

Antti A, Salava A, Perälä M, Pelkonen AS, Mäkelä MJ, Remitz A. Antti A, et al. Among authors: perala m. Acta Derm Venereol. 2021 Jan 5;101(1):adv00368. doi: 10.2340/00015555-3739. Acta Derm Venereol. 2021. PMID: 33372683 Free PMC article. No abstract available.

4

Effective treatment of atopic dermatitis in small children significantly improves the quality of life of patients and their families.

Salava A, Perälä M, Juppo M, Pelkonen AS, Mäkelä MJ, Remitz A. Salava A, et al. Among authors: perala m. Eur J Dermatol. 2021 Dec 1;31(6):791-797. doi: 10.1684/ejd.2021.4169. Eur J Dermatol. 2021. PMID: 34935622

5

Topical tacrolimus versus corticosteroids in childhood moderate-to-severe atopic dermatitis and the impact on airway inflammation: a long-term randomized open-label study.

Perälä M, Salava A, Malmberg P, Pelkonen AS, Mäkelä MJ, Remitz A. Perälä M, et al. Clin Exp Dermatol. 2023 Jun 5;48(6):660-666. doi: 10.1093/ced/llad098. Clin Exp Dermatol. 2023. PMID: 36916653 Clinical Trial.

6

Relevance of Coding Variation in FLG And DOCK8 in Finnish Pediatric Patients with Early-Onset Moderate-To-Severe Atopic Dermatitis.

Perälä M, Kaustio M, Salava A, Jakkula E, Pelkonen AS, Saarela J, Remitz A, Mäkelä MJ. Perälä M, et al. JID Innov. 2023 Apr 4;3(4):100203. doi: 10.1016/j.xjidi.2023.100203. eCollection 2023 Jul. JID Innov. 2023. PMID: 37533579 Free PMC article.

7

Morbidity of very young infants with and without acute otitis media.

Karma P, Perälä M, Kuusela AL. Karma P, et al. Among authors: perala m. Acta Otolaryngol. 1989 May-Jun;107(5-6):460-6. doi: 10.3109/00016488909127541. Acta Otolaryngol. 1989. PMID: 2756838

8

Mequitazine and dexchlorpheniramine in perennial rhinitis. A double-blind cross-over placebo-controlled study.

Pukander JS, Karma PH, Penttilä MA, Perälä ME, Ylitalo P, Kataja MJ. Pukander JS, et al. Among authors: perala me. Rhinology. 1990 Dec;28(4):249-56. Rhinology. 1990. PMID: 2293320 Clinical Trial.

9

Characterization of the 5' flanking region of the Escherichia coli ppa gene encoding inorganic pyrophosphatase: mutations in the ribosome-binding site decrease the level of ppa mRNA.

Lahti R, Perälä M, Heikinheimo P, Pitkäranta T, Kukko-Kalske E, Heinonen J. Lahti R, et al. Among authors: perala m. J Gen Microbiol. 1991 Nov;137(11):2517-23. doi: 10.1099/00221287-137-11-2517. J Gen Microbiol. 1991. PMID: 1664458

10

Biodistribution in normal mice of an 111In-labelled prostatic acid phosphatase-specific antibody and its F(ab')2 fragments derivatized site-specifically or via bicyclic diethylenetriaminepentaacetic acid anhydride.

Perälä M, Vihko P, Södervall M, Heikkilä J, Vihko R. Perälä M, et al. Eur J Nucl Med. 1990;16(8-10):621-6. doi: 10.1007/BF00998159. Eur J Nucl Med. 1990. PMID: 2384100

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters